David W. Anderson, Ph.D.

Non-clinical Development

David Anderson, Ph.D. has deep expertise in target-based drug discovery/ development and personalized molecular diagnostics in inflammation and oncology. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation and Cypress Bioscience.

Anderson has held senior positions at Ignyta (CSO/ VP Cancer Biology), Eclipse Therapeutics (VP R&D acquired by Bionomics), Proprius Pharmaceuticals, (CSO) Celgene Corporation (CSO/Senior VP), Johnson & Johnson (Senior Director Immunotherapy/ Inflammation Drug Discovery), and Monsanto/ Searle (Senior Group Leader). He has served as a consultant for numerous other companies (Johnson & Johnson, Celgene, Santarus/Salix, Adventrx, aTyr Pharma), VC and investment firms (Kleiner Perkins Caufield & Byers, Venrock Ventures, CID Equity Partners & Clarian Health, City Hill Ventures) and as an SAB member (Visionary Pharmaceuticals, Capella Therapeutics).